Aptose Biosciences (TSE:APS – Get Rating) (NASDAQ:APTO)‘s stock had its “overweight” rating reissued by stock analysts at Cantor Fitzgerald in a note issued to investors on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Aptose Biosciences’ FY2022 earnings at ($0.60) EPS and FY2023 earnings at ($0.56) EPS.
Separately, Jonestrading reaffirmed a “buy” rating and issued a C$5.00 target price on shares of Aptose Biosciences in a report on Friday, June 3rd.
Aptose Biosciences Stock Down 5.9 %
Shares of TSE:APS opened at C$0.80 on Wednesday. The firm has a 50 day simple moving average of C$1.01 and a 200-day simple moving average of C$1.24. The company has a market capitalization of C$73.84 million and a PE ratio of -0.91. Aptose Biosciences has a twelve month low of C$0.79 and a twelve month high of C$3.53. The company has a current ratio of 6.89, a quick ratio of 6.70 and a debt-to-equity ratio of 0.72.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.